NKTR Nektar Therapeutics - Common Stock
NASDAQ · Pharmaceuticals · SEC EDGAR에서 보기 ↗ 종가 10월 2, 2026 10-K/10-Q 8월 14, 2026
$43.58
· 52주 범위 %
· 저점 이상
· 고점까지
$33.4052주 저점
$109.0052주 고점
시가총액 (MRQ)
$888M
P/E (TTM)
-4.5
EPS (TTM)
$-9.59
매출 (TTM)
$55M
내 배지
52주 범위
$33–$109
애널리스트 평점
BUY
목표 주가
$141
P/E
-4.5
ROE
-35.8%
순이익률
-287.8%
배지 스트립이 비어 있습니다. 이 페이지의 아무 지표나 고정하세요.
NKTR 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$43.58
시가총액 (MRQ)
$888M
P/E (TTM)
-4.5
EPS (TTM)
$-9.59
매출 (TTM)
$55M
ROE (TTM)
-35.8%
52주 범위
$33–$109
NKTR 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
범위
막대
막대 세분성은 선택한 기간에 따라 조정됩니다. 막대의 시가/고가/저가/종가를 보려면 차트에 마우스를 올리세요.
주식 분할
| 배당락일 | 분할 | 유형 |
|---|---|---|
| 2025년 6월 9일 | 1-for-15 | 역방향 |
| 2000년 8월 23일 | 2-for-1 | 정방향 |
Nektar Therapeutics - Common Stock 정보 위키백과 회사 개요
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Background
The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.
In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.
As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees.
Pipeline
Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. The European Medicines Agency refused a marketing authorisation in 2017.
Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, Phase I results were announced in November 2016. It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.
In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
섹터Healthcare
산업Pharmaceuticals
직원63
국가US
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출$55M2016-12-31 → 2025-12-31
EPS$-9.732016-12-31 → 2025-12-31
잉여현금흐름$-209M2016-12-31 → 2025-12-31
순이익률-287.8%2016-12-31 → 2025-12-31
가치 평가 및 비율
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
| 지표 | 5년 추세 | NKTR | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| P/E (TTM) | -4.55년 평균 ≈-20.0 | ≈-20.0 | · | · | |
| P/S (TTM) | 16.35년 평균 ≈99.6 | ≈99.6 | 4.5 | 고평가 | |
| P/B (MRQ) | 1.05년 평균 ≈27.5 | ≈27.5 | 7.2 | 저평가 | |
| 주가 / FCF (TTM) | -3.85년 평균 ≈-27.1 | ≈-27.1 | · | · | |
| 주가 / 현금 흐름 (TTM) | -3.85년 평균 ≈-27.9 | ≈-27.9 | · | · | |
| Price / Tangible Book (주가 / 유형 장부 가치) | 14.35년 평균 ≈29.8 | ≈29.8 | · | · |
동종 기업 중앙값은 지표별로 표준화된 기준으로 계산되며, 이 주식에 표시된 TTM/MRQ 기준과 항상 일치하지 않을 수 있습니다.
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
| 지표 | 5년 추세 | NKTR | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 영업이익률 (TTM) | -257.8%5년 평균 ≈-299.9% | ≈-299.9% | -26.5% | 약함 | |
| EBITDA Margin (EBITDA 마진) | -253.7%5년 평균 ≈-292.3% | ≈-292.3% | -18.9% | 약함 | |
| 세전 마진 (TTM) | -296.5%5년 평균 ≈-327.0% | ≈-327.0% | -14.3% | 약함 | |
| 순이익률 (TTM) | -287.8%5년 평균 ≈-327.6% | ≈-327.6% | -10.7% | 약함 | |
| ROA (TTM) | -24.1%5년 평균 ≈-43.9% | ≈-43.9% | -12.8% | 약함 | |
| ROE (TTM) | -35.8%5년 평균 ≈-214.5% | ≈-214.5% | -21.0% | 약함 | |
| ROIC | -155.8%5년 평균 ≈-139.8% | ≈-139.8% | -22.1% | 약함 |
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
| 지표 | 5년 추세 | NKTR | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 유동비율 (MRQ) | 10.45년 평균 ≈6.6 | ≈6.6 | 5.5 | 강한 유동성 | |
| Quick Ratio (당좌 비율) | 0.35년 평균 ≈0.7 | ≈0.7 | 1.5 | 낮은 유동성 |
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
| 지표 | 5년 추세 | NKTR | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Revenue YoY (매출 YoY) | -43.9%5년 평균 ≈-16.0% | ≈-16.0% | · | · | |
| Revenue CAGR 3Y (매출 CAGR 3년) | -15.7%5년 평균 ≈-11.0% | ≈-11.0% | · | · | |
| Revenue CAGR 5Y (매출 CAGR 5년) | -18.4% | · | · | · |
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
| 지표 | 5년 추세 | NKTR | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Asset Turnover (자산 회전율) | 0.25년 평균 ≈0.2 | ≈0.2 | 0.5 | 약함 | |
| Revenue / Employee (연간 매출액 ÷ 직원 수(yfinance 보고 인원수). 파생 — 저장된 SEC-XBRL 개념이 아님.) | ≈$876.7K | · | · | · |
가치 · ≈ 5년 평균 · 산업 중앙값 · 중앙값 대비 평가
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
8.3%
다음 실적
11월 04, 2026
| 기간 | 보고서 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|---|
| 2026년 6월 30일 | 8월 13, 2026 | $-1.23 | $-2.02 | 39.2% |
| 2026년 3월 31일 | 5월 7, 2026 | $-1.82 | $-1.63 | -11.9% |
| 2025년 12월 31일 | $-1.78 | $-2.52 | 29.5% | |
| 2025년 9월 30일 | $-1.87 | $-2.74 | 31.7% | |
| 2025년 6월 30일 | $-2.95 | $-3.10 | 4.7% | |
| 2025년 3월 31일 | $-3.60 | $-2.51 | -43.2% |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Cost of Revenue | $0 | $31M | $34M | $22M | $25M | $19M | $21M | $24M | $31M | $30M | $34M | $29M | |
| R&D Expense | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M | $183M | $148M | |
| SG&A Expense | $69M | $77M | $77M | $92M | $123M | $105M | $99M | $81M | $52M | $44M | $43M | $41M | |
| Operating Expenses | $195M | $204M | $354M | $468M | $548M | $578M | $555M | $505M | $367M | $278M | $260M | $217M | |
| Operating Income | $-140M | $-105M | $-264M | $-376M | $-446M | $-425M | $-440M | $688M | $-60M | $-113M | $-29M | $-16M | |
| Interest Expense | · | · | · | $0 | $0 | $7M | $21M | $22M | $22M | $22M | $18M | $18M | |
| Interest Income | $10M | $14M | $19M | $7M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $361.0K | $-390.0K | $-6M | $-116.0K | $-162.0K | $18M | $46M | $38M | $5M | $2M | $2M | $814.0K | |
| Pretax Income | $-164M | $-119M | $-276M | $-365M | $-523M | $-444M | $-440M | $683M | $-96M | $-153M | $-81M | $-54M | |
| Income Tax | $-138.0K | $-239.0K | $-200.0K | $3M | $557.0K | $493.0K | $613.0K | $1M | $616.0K | $876.0K | $506.0K | $-512.0K | |
| Net Income | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 | $-0.62 | $-1.10 | · | · | |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | · | · | |
| Shares (Basic) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 169,600,000 | 155,953,000 | 139,596,000 | · | · | |
| Shares (Diluted) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 180,119,000 | 155,953,000 | 139,596,000 | · | · | |
| EBITDA | $-140M | $-101M | $-257M | $-364M | $-433M | $-413M | $-429M | $697M | $-47M | $-113M | $-29M | · |
대차대조표
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $44M | $35M | $88M | $25M | $199M | $96M | $195M | $5M | $60M | $56M | $12M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $291M | $329M | $253M | $225M | |
| Receivables | · | $0 | $1M | $6M | $22M | $39M | $37M | $43M | $5M | $16M | $20M | $4M | |
| Inventory | $0 | $0 | $16M | $19M | $16M | $15M | $13M | $11M | $11M | $11M | $11M | $13M | |
| Other Current Assets | $21M | $6M | $10M | $16M | $23M | $22M | $15M | $21M | $8M | $10M | $10M | $9M | |
| Current Assets | $266M | $261M | $331M | $546M | $796M | $1.14B | $1.42B | $1.44B | $327M | $426M | $350M | $288M | |
| PP&E (Net) | $2M | $3M | $19M | $32M | $61M | $60M | $66M | $49M | $47M | $66M | $71M | $70M | |
| Accum. Depreciation | · | $16M | $87M | $125M | $148M | $138M | $128M | $121M | $115M | $111M | $103M | $94M | |
| Goodwill | · | · | $0 | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | |
| Other Non-current Assets | $14M | $5M | $5M | $2M | $3M | $1M | $344.0K | $4M | $994.0K | $817.0K | $754.0K | $7M | |
| Total Assets | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Accounts Payable | $11M | $12M | $10M | $13M | $10M | $22M | $19M | $6M | $5M | $3M | $2M | $3M | |
| Accrued Liabilities | $22M | $30M | $22M | $37M | · | · | · | · | · | · | · | $6M | |
| Current Liabilities | $54M | $61M | $51M | $68M | $85M | $116M | $354M | $82M | $56M | $72M | $61M | $64M | |
| Capital Leases | $65M | $83M | $99M | $113M | $126M | $136M | $143M | $0 | · | $2M | $1M | $4M | |
| Other Non-current Liabilities | $9M | $7M | $5M | $8M | $4M | $9M | $768.0K | $10M | $6M | $7M | $10M | $15M | |
| Total Liabilities | $191M | $243M | $267M | $344M | $438M | $461M | $572M | $433M | $421M | $481M | $492M | $405M | |
| Common Stock | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K | $18.0K | $17.0K | $17.0K | $15.0K | $15.0K | $13.0K | $13.0K | |
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B | $-2.12B | $-2.02B | $-1.87B | $-1.79B | |
| Treasury Stock | · | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $17.0K | $61.0K | $80.0K | $-7M | $-4M | $-2M | $-1M | $-6M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $90M | $61M | $131M | $367M | $680M | $1.08B | $1.41B | $1.72B | $88M | $88M | $6M | $36M | |
| Liabilities + Equity | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Shares Outstanding | 20,378,832 | 12,385,001 | 12,757,984 | 188,560,000 | 185,468,000 | 180,091,000 | 176,505,000 | 173,530,000 | 159,524,000 | 153,212,000 | 135,289,000 | 131,216,000 |
현금 흐름
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $4M | $7M | $12M | $13M | $12M | $11M | $9M | $13M | $13M | $11M | $13M | |
| Stock-based Comp | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Deferred Tax | $64.0K | $-10.0K | $-140.0K | $3M | $-102.0K | $-36.0K | $-21.0K | $93.0K | $35.0K | $-115.0K | $-22.0K | $-31.0K | |
| Other Non-cash | · | $-61M | $77M | $49M | $98M | $119M | $101M | $28M | $4M | · | · | · | |
| Operating Cash Flow | $-209M | $-176M | $-193M | $-304M | $-413M | $-313M | $-329M | $718M | $-80M | $-117M | $-73M | $-142M | |
| CapEx | $171.0K | $1M | $865.0K | $6M | $15M | $7M | $26M | $14M | $10M | $6M | $11M | $10M | |
| Investing Cash Flow | $-1M | $143M | $140M | $366M | $203M | $496M | $207M | $-1.38B | $-29M | $-82M | · | · | |
| Stock Repurchased | $0 | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $181M | $42M | $30.0K | $2M | $36M | $-80M | $23M | $852M | $54M | $204M | · | · | |
| Net Change in Cash | $-29M | $9M | $-53M | $63M | $-174M | $103M | $-99M | $190M | $-55M | $4M | $43M | $-27M | |
| Taxes Paid | $-195.0K | $76.0K | $3M | $272.0K | $325.0K | $539.0K | $555.0K | $618.0K | $556.0K | $757.0K | $860.0K | $964.0K | |
| Free Cash Flow | $-209M | $-177M | $-193M | $-310M | $-428M | $-321M | $-355M | $704M | $-90M | $-123M | $-84M | · | |
| Levered FCF | · | · | · | $-310M | $-428M | $-327M | $-376M | $682M | $-112M | $-146M | $-103M | · |
수익성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% | · | |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% | · | |
| Pretax Margin | -297.3% | -121.1% | -306.5% | -396.5% | -513.5% | -290.3% | -383.9% | 57.2% | -31.2% | -92.3% | -35.0% | · | |
| EBITDA Margin | -253.7% | -102.7% | -284.8% | -395.4% | -425.0% | -269.8% | -374.3% | 58.4% | -15.3% | -68.2% | -12.7% | · | |
| ROA | -56.2% | -33.9% | -49.8% | -40.3% | -39.5% | -25.3% | -21.3% | 51.2% | -17.9% | -28.8% | -17.2% | · | |
| ROE | -500.1% | -217.0% | -190.2% | -94.5% | -70.7% | -39.5% | -30.4% | 38.9% | -109.9% | -324.7% | -379.7% | · | |
| ROIC | -155.8% | -172.9% | -201.2% | -103.5% | -65.7% | -39.5% | -31.4% | 40.0% | -68.3% | -128.8% | -459.7% | · |
유동성 및 지급능력
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 | 9.8 | 4.0 | 17.5 | 5.8 | 5.9 | 5.7 | · | |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 | 2.1 | 0.4 | 2.9 | 5.4 | 5.6 | 5.4 | · | |
| Interest Coverage | · | · | · | · | · | -62.1 | -20.6 | 31.9 | -2.7 | -5.0 | -1.6 | · |
효율성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | 0.6 | 0.3 | 0.5 | · | |
| Inventory Turnover | · | 3.8 | 1.9 | 1.2 | 1.6 | 1.4 | 1.8 | 2.2 | 2.8 | 2.7 | 2.8 | · | |
| Receivables Turnover | · | 163.4 | 25.1 | 6.5 | 3.3 | 4.0 | 2.9 | 49.5 | 29.7 | 9.3 | 19.6 | · |
주당
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.41 | $0.33 | $0.68 | $1.94 | $3.66 | $5.98 | $7.96 | $9.90 | $0.55 | $0.58 | $0.05 | · | |
| Revenue / Share | $3.27 | $0.48 | $0.47 | $0.49 | $0.56 | $0.86 | $0.66 | $6.63 | · | · | · | · | |
| Cash Flow / Share | $-12.36 | $-0.85 | $-1.01 | $-1.62 | $-2.25 | $-1.75 | $-1.88 | $3.99 | · | · | · | · | |
| Cash / Share | $0.74 | $0.24 | $0.18 | $0.47 | $0.14 | $1.10 | $0.55 | $1.12 | $0.03 | $0.39 | $0.41 | · | |
| EPS (TTM) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | $-0.61 | $-0.45 |
성장률
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -15.7% | -1.1% | -16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -18.4% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM)
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Net Income TTM | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| Market Cap | $862M | $2.59B | $1.61B | $6.39B | $37.59B | $45.92B | $57.16B | $85.56B | $142.90B | $28.20B | $34.19B | · | |
| P/E | -4.3 | -1.6 | -5.8 | -17.2 | -70.9 | -102.4 | -128.5 | 130.4 | -1444.8 | -167.3 | -414.3 | -516.7 | |
| P/S | 15.6 | 26.3 | 17.8 | 69.4 | 368.8 | 300.3 | 498.7 | 71.7 | 464.4 | 170.5 | 148.2 | · | |
| P/B | 9.6 | 42.7 | 12.3 | 17.4 | 55.3 | 42.6 | 40.7 | 49.8 | 1627.1 | 320.0 | 5318.8 | · | |
| P / Tangible Book | 9.6 | 42.7 | 12.3 | 22.0 | 62.3 | 45.9 | · | · | · | · | · | · | |
| P / Cash Flow | -4.1 | -14.7 | -8.3 | -21.0 | -91.1 | -146.6 | -173.9 | 119.1 | -1777.1 | -241.0 | -467.9 | · | |
| P / FCF | -4.1 | -14.6 | -8.3 | -20.6 | -87.9 | -143.3 | -161.0 | 121.5 | -1586.2 | -228.5 | -405.7 | · | |
| Earnings Yield | -23.0% | -62.2% | -17.3% | -5.8% | -1.4% | -0.98% | -0.78% | 0.77% | -0.07% | -0.60% | -0.24% | -0.19% |
손익계산서
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $22M | $12M | $11M | $10M | $29M | $24M | $23M | $22M | $24M | $24M | $20M | $22M | $22M | $24M | |
| Cost of Revenue | · | · | $0 | $0 | $0 | $0 | $8M | $4M | $10M | $9M | $7M | $12M | $7M | $7M | $6M | $5M | |
| R&D Expense | $39M | $36M | $30M | $27M | $30M | $30M | $29M | $35M | $30M | $27M | $30M | $24M | $30M | $30M | $35M | $34M | |
| SG&A Expense | $13M | $13M | $11M | $16M | $17M | $24M | $17M | $19M | $21M | $20M | $17M | $21M | $18M | $21M | $22M | $23M | |
| Operating Expenses | $52M | $50M | $49M | $43M | $47M | $55M | $15M | $58M | $73M | $57M | $57M | $69M | $71M | $156M | $74M | $78M | |
| Operating Income | $-42M | $-39M | $-28M | $-32M | $-36M | $-45M | $14M | $-34M | $-50M | $-35M | $-34M | $-45M | $-51M | $-135M | $-52M | $-54M | |
| Interest Income | $9M | $4M | $3M | $3M | $2M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | · | · | |
| Other Non-op | $-100.0K | $-336.0K | $-44.0K | $-121.0K | $260.0K | $266.0K | $-135.0K | $-120.0K | $-36.0K | $-99.0K | $-6M | $-335.0K | $736.0K | $-301.0K | $-4M | $2M | |
| Pretax Income | $-40M | $-43M | $-43M | $-35M | $-39M | $-46M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-57M | $-59M | |
| Income Tax | $2.0K | $64.0K | $31.0K | $-33.0K | $-188.0K | $52.0K | $-259.0K | $9.0K | $46.0K | $-35.0K | $-29.0K | $-61.0K | $-47.0K | $-63.0K | $3M | $-155.0K | |
| Net Income | $-41M | $-45M | $-36M | $-36M | $-42M | $-51M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-60M | $-59M | |
| EPS (Basic) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| EPS (Diluted) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| Shares (Basic) | 33,054,865 | 24,736,066 | · | 18,946,559 | 14,087,307 | 14,063,402 | · | 13,949,851 | 13,921,378 | 194,746,000 | · | 190,406,000 | 189,656,000 | 188,875,000 | · | 187,641,000 | |
| Shares (Diluted) | 33,054,865 | 24,736,066 | · | 18,946,559 | 14,087,307 | 14,063,402 | · | 13,949,851 | 13,921,378 | 194,746,000 | · | 190,406,000 | 189,656,000 | 188,875,000 | · | 187,641,000 | |
| EBITDA | $-42M | $-39M | · | $-32M | $-36M | $-45M | · | $-34M | $-50M | $-35M | · | $-45M | $-51M | $-135M | · | $-54M |
대차대조표
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M | $49M | $35M | $65M | $51M | $77M | $88M | $106M | |
| Receivables | · | · | · | · | · | · | · | $0 | $1M | $4M | $1M | $2M | $1M | $3M | $6M | $12M | |
| Inventory | · | · | $0 | · | · | · | $0 | $0 | $14M | $16M | $16M | $15M | $21M | $20M | $19M | $19M | |
| Other Current Assets | $55M | $20M | $21M | $11M | $11M | $11M | $6M | $9M | $8M | $11M | $10M | $9M | $10M | $11M | $16M | $23M | |
| Current Assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M | $320M | $331M | $399M | $441M | $491M | $546M | $599M | |
| PP&E (Net) | · | · | $2M | $3M | $3M | $3M | $3M | $4M | $15M | $17M | $19M | $20M | $23M | $27M | $32M | $37M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $16M | $88M | · | $87M | $88M | $108M | $111M | $125M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $77M | $77M | |
| Other Non-current Assets | $17M | $11M | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $2M | $1M | $2M | $2M | |
| Total Assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Accounts Payable | $25M | $10M | $11M | $16M | $14M | $18M | $12M | $9M | $6M | $9M | $10M | $3M | $3M | $4M | $13M | $5M | |
| Accrued Liabilities | $23M | $25M | $22M | $29M | $35M | $31M | $30M | $32M | $30M | $24M | $22M | $30M | $29M | $37M | $37M | · | |
| Current Liabilities | $71M | $58M | $54M | $66M | $71M | $71M | $61M | $68M | $57M | $52M | $51M | $52M | $51M | $60M | $68M | $84M | |
| Capital Leases | $56M | $61M | $65M | $70M | $74M | $78M | $83M | $87M | $91M | $95M | $99M | $102M | $106M | $109M | $113M | $116M | |
| Other Non-current Liabilities | $8M | $8M | $9M | $5M | $6M | $7M | $7M | $7M | $8M | $4M | $5M | $5M | $5M | $6M | $8M | $3M | |
| Total Liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M | $269M | $267M | $283M | $297M | $321M | $344M | $369M | |
| Common Stock | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | |
| Retained Earnings | $-3.85B | $-3.81B | $-3.76B | $-3.72B | $-3.69B | $-3.65B | $-3.60B | $-3.60B | $-3.57B | $-3.51B | $-3.48B | $-3.44B | $-3.39B | $-3.34B | $-3.20B | $-3.14B | |
| Treasury Stock | · | · | · | $0 | $3M | $3M | $3M | $3M | $3M | $3M | · | · | · | · | · | · | |
| AOCI | $-2M | $-1M | $17.0K | $56.0K | $-14.0K | $39.0K | $61.0K | $355.0K | $-494.0K | $-403.0K | $80.0K | $-6M | $-6M | $-6M | $-7M | $-8M | |
| Stockholders' Equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M | $127M | $131M | $159M | $197M | $241M | $367M | $412M | |
| Liabilities + Equity | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Shares Outstanding | 20,378,832 | 20,378,832 | 20,378,832 | 19,652,513 | 12,457,252 | 186,103,000 | 12,385,001 | 184,458,000 | 184,061,000 | 183,624,000 | 191,384,000 | 190,771,000 | 190,119,000 | 189,235,000 | 188,560,000 | 187,954,000 |
현금 흐름
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $156.0K | $151.0K | $190.0K | $196.0K | $214.0K | $426.0K | $332.0K | $993.0K | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $2.0K | $-31.0K | $57.0K | $-38.0K | $2M | $-15.0K | $-27.0K | $-2M | $3M | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Operating Cash Flow | $-76M | $-44M | $-65M | $-49M | $-46M | $-49M | $-46M | $-44M | $-38M | $-48M | $-47M | $-42M | $-52M | $-52M | $-58M | $-83M | |
| CapEx | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K | $186.0K | $157.0K | $237.0K | $33.0K | $162.0K | $433.0K | $512.0K | $181.0K | |
| Investing Cash Flow | $-399M | $-351M | $372.0K | $-95M | $50M | $44M | $60M | $46M | $17M | $19M | $17M | $56M | $25M | $41M | $40M | $111M | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3M | · | · | · | · | · | · | |
| Financing Cash Flow | $365M | $530M | $39M | $142M | $211.0K | $7.0K | $83.0K | $13.0K | $19.0K | $42M | $12.0K | $0 | $18.0K | $0 | $103.0K | $0 | |
| Net Change in Cash | $-110M | $134M | $-26M | $-2M | $4M | $-5M | $14M | $2M | $-21M | $13M | $-30M | $14M | $-26M | $-11M | $-18M | $28M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | $272.0K | $-85.0K | |
| Free Cash Flow | · | $-44M | · | · | · | $-49M | · | · | · | $-48M | · | · | · | $-52M | · | · |
수익성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| Net Margin | -401.0% | -413.4% | · | -301.3% | -372.2% | -486.4% | · | -153.6% | -222.9% | -170.1% | · | -189.8% | -249.4% | -634.5% | · | -249.9% | |
| Pretax Margin | -397.8% | -396.7% | · | -297.0% | -352.5% | -443.3% | · | -153.6% | -222.7% | -170.2% | · | -190.1% | -249.6% | -634.8% | · | -250.6% | |
| EBITDA Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| ROA | -6.2% | -8.8% | · | -11.7% | -15.1% | -15.6% | · | -9.9% | -12.5% | -7.7% | · | -7.5% | -7.5% | -17.3% | · | -5.7% | |
| ROE | -9.2% | -15.2% | · | -53.0% | -150.0% | -72.5% | · | -35.6% | -37.9% | -20.0% | · | -16.0% | -15.6% | -32.3% | · | -9.7% | |
| ROIC | -4.7% | -6.8% | · | -37.2% | 148.9% | -324.5% | · | -70.3% | -62.5% | -27.9% | · | -28.1% | -25.7% | -55.9% | · | -13.1% |
유동성 및 지급능력
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.4 | 10.2 | · | 4.2 | 2.6 | 3.2 | · | 4.2 | 5.1 | 6.1 | · | 7.7 | 8.7 | 8.2 | · | 7.1 | |
| Quick Ratio | 0.6 | 2.6 | · | 0.6 | 0.6 | 0.5 | · | 0.4 | 0.5 | 1.0 | · | 1.3 | 1.0 | 1.3 | · | 1.4 |
효율성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.6 | 0.6 | 0.5 | · | 0.7 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | 21.9 | 18.6 | 6.5 | · | 3.5 | 3.6 | 1.3 | · | 1.2 |
주당
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $44.32 | $28.28 | · | $4.33 | $-1.94 | $0.07 | · | $0.27 | $0.43 | $0.69 | · | $0.84 | $1.04 | $1.27 | · | $2.19 | |
| Revenue / Share | $0.31 | $0.44 | · | $0.62 | $0.79 | $0.05 | · | $0.12 | $0.11 | $0.11 | · | $0.13 | $0.11 | $0.11 | · | $0.13 | |
| Cash Flow / Share | · | $-1.79 | · | · | · | $-0.23 | · | · | · | $-0.25 | · | · | · | $-0.27 | · | · | |
| Cash / Share | $1.93 | $7.34 | · | $2.09 | $3.45 | $0.21 | · | $0.16 | $0.15 | $0.26 | · | $0.34 | $0.27 | $0.41 | · | $0.56 | |
| EPS (TTM) | $-9.59 | $-11.31 | · | $-10.51 | $-11.30 | $-12.11 | · | $-6.82 | $-4.40 | $-0.91 | · | $-1.56 | $-1.63 | $-2.21 | · | $-2.44 |
가치 평가 (TTM)
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $56M | · | $63M | $75M | $87M | · | $93M | $93M | $90M | · | $88M | $88M | $89M | · | $95M | |
| Net Income TTM | $-157M | $-158M | · | $-121M | $-122M | $-133M | · | $-168M | $-177M | $-176M | · | $-294M | $-307M | $-415M | · | $-454M | |
| Market Cap | $1.42B | $1.47B | · | $1.12B | $322M | $1.90B | · | $3.60B | $3.42B | $2.56B | · | $1.72B | $1.65B | $1.99B | · | $9.02B | |
| P/E | -7.3 | -6.4 | · | -5.4 | -2.3 | -0.8 | · | -2.9 | -4.2 | -15.3 | · | -5.8 | -5.3 | -4.8 | · | -19.7 | |
| P/S | 26.1 | 26.4 | · | 17.9 | 4.3 | 21.8 | · | 38.6 | 36.8 | 28.4 | · | 19.5 | 18.9 | 22.4 | · | 94.9 | |
| P/B | 1.6 | 2.5 | · | 13.1 | -13.3 | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 21.9 | |
| P / Tangible Book | 1.6 | 2.5 | · | 13.1 | · | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 26.9 | |
| P / Cash Flow | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.5 | · | · | · | -38.3 | · | · | |
| Earnings Yield | -13.7% | -15.7% | · | -18.5% | -43.7% | -118.7% | · | -35.0% | -23.7% | -6.5% | · | -17.3% | -18.7% | -21.1% | · | -5.1% |
최신 기간은 왼쪽에 · null 값은 ·로 표시
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 매출 | $55M | $98M | $90M | $92M | $102M |
| 영업이익률 % | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| 순이익 | $-164M | $-119M | $-276M | $-368M | $-524M |
| 희석 EPS | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 유동비율 | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 |
| 당좌 비율 | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 잉여현금흐름 | $-209M | $-177M | $-193M | $-310M | $-428M |
기관 투자자 (13F) 267개의 제출자 · $2.7B 전체 · 기준일 2026년 9월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
보유자
267
보유 가치
$2.7B
신규 포지션
78
청산 포지션
42
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 78 (+2 이전 분기 대비) | 42 (+11 이전 분기 대비) | 105 (+27 이전 분기 대비) | 44 (-6 이전 분기 대비) | +10.6M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| FMR LLC | $353,791,520 | 5,067,920 | 13.17% | 주식 |
| Two Seas Capital LP | $215,868,856 | 3,092,234 | 8.04% | 주식 |
| BlackRock, Inc. | $205,370,620 | 2,941,851 | 7.64% | 주식 |
| BVF INC/IL | $166,920,946 | 2,391,075 | 6.21% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $104,495,029 | 1,496,849 | 3.89% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $83,911,899 | 1,202,004 | 3.12% | 주식 |
| Vestal Point Capital, LP | $69,810,000 | 1,000,000 | 2.60% | 주식 |
| MORGAN STANLEY | $65,381,263 | 936,560 | 2.43% | 주식 |
| STATE STREET CORP | $63,504,691 | 909,679 | 2.36% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $61,536,312 | 881,306 | 2.29% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57,502,497 | 823,700 | 2.14% | 콜 옵션 |
| Prosight Management, LP | $56,546,100 | 810,000 | 2.10% | 주식 |
| ARMISTICE CAPITAL, LLC | $50,542,440 | 724,000 | 1.88% | 주식 |
| VANGUARD GROUP INC | $43,425,322 | 1,027,089 | 1.62% | 주식 |
| GILDER GAGNON HOWE & CO LLC | $41,946,944 | 600,873 | 1.56% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $33,377,557 | 478,120 | 1.24% | 주식 |
| BRAIDWELL LP | $33,063,203 | 473,617 | 1.23% | 주식 |
| Sofinnova Investments, Inc. | $32,933,775 | 471,763 | 1.23% | 주식 |
| Woodline Partners LP | $32,871,784 | 470,875 | 1.22% | 주식 |
| ORBIMED ADVISORS LLC | $32,485,804 | 465,346 | 1.21% | 주식 |
| UBS Group AG | $29,906,604 | 428,400 | 1.11% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $27,540,045 | 394,500 | 1.03% | 풋 옵션 |
| EMERALD ADVISERS, LLC | $27,236,930 | 390,158 | 1.01% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $24,331,577 | 348,540 | 0.91% | 주식 |
| DAFNA Capital Management LLC | $22,226,108 | 318,380 | 0.83% | 주식 |
| NORTHERN TRUST CORP | $21,538,548 | 308,531 | 0.80% | 주식 |
| Deep Track Capital, LP | $20,943,000 | 300,000 | 0.78% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19,893,826 | 284,971 | 0.74% | 주식 |
| 22NW, LP | $19,624,638 | 281,115 | 0.73% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19,475,384 | 278,977 | 0.72% | 주식 |
| PRIMECAP MANAGEMENT CO/CA/ | $19,047,658 | 272,850 | 0.71% | 주식 |
| BARCLAYS PLC | $18,315,491 | 262,362 | 0.68% | 주식 |
| Nearwater Capital Markets, Ltd | $18,255,315 | 261,500 | 0.68% | 주식 |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17,842,528 | 255,587 | 0.66% | 주식 |
| ADAR1 Capital Management, LLC | $17,046,485 | 244,184 | 0.63% | 주식 |
| Creek Drive Management Group LLC | $16,963,830 | 243,000 | 0.63% | 주식 |
| SEVEN GRAND MANAGERS, LLC | $16,754,400 | 240,000 | 0.62% | 주식 |
| DEUTSCHE BANK AG\ | $16,742,602 | 239,831 | 0.62% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $16,724,731 | 239,575 | 0.62% | 주식 |
| GOLDMAN SACHS GROUP INC | $15,950,887 | 228,490 | 0.59% | 주식 |
| NORGES BANK | $15,030,093 | 215,300 | 0.56% | 주식 |
| Bronte Capital Management Pty Ltd. | $13,852,678 | 198,434 | 0.52% | 주식 |
| TWO SIGMA ADVISERS, LP | $13,039,744 | 308,414 | 0.49% | 주식 |
| CITADEL ADVISORS LLC | $12,251,655 | 175,500 | 0.46% | 풋 옵션 |
| GREAT POINT PARTNERS LLC | $12,216,750 | 175,000 | 0.45% | 주식 |
| Caption Management, LLC | $11,944,491 | 171,100 | 0.44% | 콜 옵션 |
| MILLENNIUM MANAGEMENT LLC | $11,867,700 | 170,000 | 0.44% | 콜 옵션 |
| AMERIPRISE FINANCIAL INC | $11,584,330 | 165,941 | 0.43% | 주식 |
| CITADEL ADVISORS LLC | $11,434,878 | 163,800 | 0.43% | 콜 옵션 |
| CITADEL ADVISORS LLC | $11,151,938 | 159,747 | 0.42% | 주식 |
행동주의자 및 5% 이상 소유자 1 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Nektar Therapeutics ( | 2005년 8월 22일 | · | 최초 제출 | M&A / 매각 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
회사 내부자 40 명의 내부자 · 20 임원 · 18 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Howard W Robin | President & CEO | 2026년 8월 18일 S | 54,627 | 0 | 8 | $-1,424,905 |
| Jillian B. Thomsen | Chief Financial Officer | 2023년 2월 16일 S | 313,497 | 0 | 0 | $0 |
| Gil M Labrucherie | SVP, COO & CFO | 2022년 5월 16일 S | 312,905 | 0 | 0 | $0 |
| Timothy Harkness | SVP & Chief Financial Officer | 2007년 8월 23일 A | · | 0 | 0 | $0 |
| Louis Drapeau | Sr. VP Finance, CFO | 2007년 5월 14일 A | 6,000 | 0 | 0 | $0 |
| Milton J Harris | President of Nektar AL | 2004년 3월 4일 S | 743,904 | 0 | 0 | $0 |
| John Nicholson | SVP & Chief Operating Officer | 2019년 8월 16일 S | 162,759 | 0 | 0 | $0 |
| Bharat M Chowrira | Chief Operating Officer | 2010년 2월 1일 A | · | 0 | 0 | $0 |
| Jonathan Zalevsky | Chief R&D Officer | 2026년 8월 18일 S | 9,570 | 0 | 7 | $-974,184 |
| Mark Andrew Wilson | Chief Legal Officer | 2025년 11월 21일 A | 21,585 | 0 | 1 | $-34,196 |
| John Northcott | SVP & Chief Commercial Officer | 2022년 5월 16일 S | 223,210 | 0 | 0 | $0 |
| Stephen K Doberstein | SVP & Chief Scientific Officer | 2019년 9월 5일 P | 107,668 | 0 | 0 | $0 |
| Maninder Hora | SVP Pharma Dev & Mfg Ops | 2019년 5월 16일 S | 94,694 | 0 | 0 | $0 |
| Ivan P. Gergel | SVP & Chief Medical Officer | 2017년 11월 15일 A | 56,553 | 0 | 0 | $0 |
| Robert Medve | SVP & Chief Medical Officer | 2014년 2월 5일 A | · | 0 | 0 | $0 |
| Rinko Ghosh | Chief Business Officer | 2013년 2월 6일 A | 9,753 | 0 | 0 | $0 |
| Randall W Moreadith | SVP Drug Development | 2009년 2월 23일 A | · | 0 | 0 | $0 |
| John Stuart Patton | Chief Scientific Officer | 2008년 11월 14일 M | 313,880 | 0 | 0 | $0 |
| Nevan C Elam | SVP & Head of Pulmonary Bus | 2008년 2월 25일 A | 1,400 | 0 | 0 | $0 |
| David Johnston | SVP, Research & Development | 2007년 5월 14일 D | 6,600 | 0 | 0 | $0 |
| Diana Brainard | 이사 | 2026년 9월 23일 A | 3,904 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | 이사 | 2026년 9월 23일 A | 4,277 | 0 | 0 | $0 |
| Robert Chess | 이사 | 2026년 9월 23일 A | 19,019 | 0 | 0 | $0 |
| Scott R Greer | 이사 | 2026년 9월 23일 A | 22,239 | 0 | 0 | $0 |
| Roy A Whitfield | 이사 | 2026년 9월 23일 A | 16,417 | 0 | 0 | $0 |
| Myriam Curet | 이사 | 2023년 9월 19일 A | 27,418 | 0 | 0 | $0 |
| Karin Eastham | 이사 | 2022년 9월 16일 A | 23,233 | 0 | 0 | $0 |
| Lutz Lingnau | 이사 | 2020년 9월 22일 A | 35,800 | 0 | 0 | $0 |
| Christopher A Kuebler | 이사 | 2018년 9월 27일 A | 45,250 | 0 | 0 | $0 |
| Dennis L Winger | 이사 | 2018년 8월 21일 M | 42,750 | 0 | 0 | $0 |
| Joseph J Krivulka | 이사 | 2017년 9월 19일 A | 82,000 | 0 | 0 | $0 |
| Susan Wang | 이사 | 2015년 11월 20일 M | 20,000 | 0 | 0 | $0 |
| BROWN MICHAEL A/CA | 이사 | 2009년 9월 15일 A | 10,000 | 0 | 0 | $0 |
| Hoyoung Huh | 이사 | 2008년 12월 2일 A | · | 0 | 0 | $0 |
| Irwin Lerner | 이사 | 2008년 12월 2일 A | 10,000 | 0 | 0 | $0 |
| James B Glavin | 이사 | 2003년 9월 4일 A | · | 0 | 0 | $0 |
| Masuoka K. Lorianne | · | 2011년 2월 8일 A | · | 0 | 0 | $0 |
| Ajit Gill | President & CEO | 2006년 3월 23일 S | 87,991 | 0 | 0 | $0 |
| Ajay Bansal | · | 2006년 3월 10일 S | 5,166 | 0 | 0 | $0 |
| Melvin Perelman | · | 2004년 9월 2일 A | · | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
ETF 보유 현황 25 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| SPIT · RBB Fund, Inc. | 2.05% | 9,695 NS | 2026년 7월 31일 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1.42% | 4,138 NS | 2026년 7월 31일 | N-PORT |
| BBC · ETFis Series Trust I | 0.80% | 5,234 NS | 2026년 7월 31일 | N-PORT |
| IHE · iShares Trust | 0.55% | 125,055 SH | 2026년 9월 11일 | 일간 |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.44% | 1,670 SH | 2026년 10월 1일 | 일간 |
| IWO · iShares Trust | 0.14% | 289,334 SH | 2026년 9월 11일 | 일간 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.13% | 33,135 SH | 2026년 8월 19일 | 일간 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.08% | 37,498 SH | 2026년 10월 1일 | 일간 |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.08% | 7,900 NS | 2026년 7월 31일 | N-PORT |
| IWM · iShares Trust | 0.08% | 879,755 SH | 2026년 9월 11일 | 일간 |
| RSSL · Global X Funds | 0.08% | 16,502 NS | 2026년 7월 31일 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.07% | 198,365 SH | 2026년 8월 19일 | 일간 |
| FHLC · FIDELITY COVINGTON TRUST | 0.03% | 14,592 NS | 2026년 7월 31일 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 387,471 SH | 2026년 8월 19일 | 일간 |
| VHT · VANGUARD WORLD FUND | 0.03% | 92,340 SH | 2026년 8월 19일 | 일간 |
| WSML · iShares Trust | 0.02% | 1,906 SH | 2026년 9월 11일 | 일간 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 3,096 SH | 2026년 8월 19일 | 일간 |
| ITOT · iShares Trust | 0.00% | 48,120 SH | 2026년 9월 11일 | 일간 |
| IWV · iShares Trust | 0.00% | 9,239 SH | 2026년 9월 11일 | 일간 |
| TILT · FlexShares Trust | 0.00% | 810 NS | 2026년 7월 31일 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,075,430 SH | 2026년 8월 19일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,837 SH | 2026년 8월 19일 | 일간 |
| IWN · iShares Trust | · | 32,591 SH | 2026년 9월 11일 | 일간 |
| ISCB · iShares Trust | · | 1,294 SH | 2026년 9월 11일 | 일간 |
| ISCV · iShares Trust | · | 6,414 SH | 2026년 9월 11일 | 일간 |
NKTR 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
평점 · 18 명의 애널리스트
매수
중앙값 목표
$150.50
+245.3%
7 38.9%
적극 매수
8 44.4%
매수
3 16.7%
보유
0 0.0%
매도
0 0.0%
적극 매도
12개월 목표 주가
10 명의 애널리스트 · 2026-09-27평균 목표 $141.40 +224.5%
← 모든 목표가 하회
현재가 $43.58
저가$50.00
평균$141.40
고가$192.00
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
회계연도 기준, 각 회사의 마지막 회계연도 말 종가 기준 가격입니다.
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| NKTR | $862M | -4.3 | -43.9% | -297.1% | -500.1% | · |
| ANIP | $1.78B | 23.8 | 43.8% | 8.9% | 16.6% | · |
| ETON | $457M | · | 104.9% | -5.8% | -18.4% | 53.5% |
| RAPP | $1.45B | -10.6 | · | · | -29.8% | · |
| OCUL | $2.62B | -8.5 | -18.5% | -511.9% | -55.4% | · |
| PAHC | · | 12.9 | 17.1% | 6.6% | 29.7% | 33.8% |
| INVA | · | 6.1 | 14.7% | · | · | · |
| MAZE | $2.04B | -13.6 | · | · | -598.9% | · |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
최신 뉴스 이 회사 관련 최근 헤드라인
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요. 상단의 전체 기본 정보에서 원하는 행 옆의 +를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
출처: SEC 10-Q 제출 8월 14, 2026